SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):  January 14, 2005
 
EXACT SCIENCES CORPORATION
(Exact Name of Registrant as Specified in its Charter)

Delaware	
(State or Other Jurisdiction of Incorporation)	
 	 	 	
000-32179	 	02-0478229	
(Commission File Number)	 	(IRS Employer Identification No.)	
 	 	 	
100 Campus Drive, Marlborough, Massachusetts	 	01752	
(Address of Principal Executive Offices)	 	(Zip Code)	
 
Registrant’s telephone number, including area code: (508) 683-1200
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Item 7.01               Regulation FD Disclosure.
 
On January 14, 2005, Exact Sciences Corporation issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K.
 
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01               Financial Statements and Exhibits.
 
(c)            Exhibits:
 
99.1                        Press Release issued by the Company on January 14, 2005, furnished herewith.
 
2

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	EXACT Sciences Corporation	

January 18, 2005	By:	/s/ Jeffrey R. Luber	 	
 	 	Jeffrey R. Luber	
 	 	General Counsel and Secretary	
 
3

 
EXHIBIT INDEX

Exhibit Number	 	Description	
 	 	 	
99.1	 	Press Release issued by the Company on January 14, 2005, furnished herewith.	
 
4

Exhibit 99.1
 
EXACT Sciences Corporation Announces Fourth Quarter and Year-End 2004 Conference Call
 
MARLBOROUGH, Mass., Jan 14, 2005 (BUSINESS WIRE) — EXACT Sciences Corporation (NASDAQ:EXAS) announced today that it will host a conference call for its fourth quarter and year- end 2004 financial and operating results on Tuesday, January 25, 2005 at 8:30 a.m. ET. A live Webcast of the conference call can be accessed at www.exactsciences.com through the Investor Relations link. The conference call and the Webcast are open to all interested parties. An archived version of the Webcast will be available at EXACT Sciences’ Web site, www.exactsciences.com, through the Investor Relations link, for one month. A replay of the conference call also will be available for 48 hours, beginning two hours after the completion of the live call.
 
EXACT Sciences will announce its fourth quarter and year- end 2004 financial and operating results on Monday, January 24, 2005, after the close of regular market trading hours.
 
•                   Information for the call is as follows:
 
•                   Domestic callers: 877-809-1575
 
•                   International callers: 706-679-5918
 
•                   Conference ID # 3354608
 
•                   The conference call replay information is as follows:
 
•                   Domestic callers: 800-642-1687
 
•                   International callers: 706-645-9291
 
•                   Conference ID # 3354608
 
The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (www.streetevents.com).
 
About EXACT Sciences Corporation
 
EXACT Sciences Corporation is the leader in rapidly applying genomics knowledge to develop effective, patient-friendly screening methods to detect cancer early, so that physicians can save patients’ lives. Its first commercial test, PreGen-Plus(TM), is used for screening for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, however, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Marlborough, Mass. Detailed information on

 
EXACT Sciences and PreGen-Plus can be found on the World Wide Web at www.exactsciences.com and www.pregenplus.com.
 
CONTACT:
EXACT Sciences Corporation
Kerry Beth Daly (Media)
617-267-8223
dalyk@fleishman.com
or
Amy Hedison (Investor Relations)
508-683-1252
ahedison@exactsciences.com